Cameroon vs Yemen: Average cost of multi drug-resistant tuberculosis treatment
Cameroon
2,825 constant 2022 US$
in 2024
Yemen
2,510 constant 2022 US$
in 2024
Cameroon rank
17th
Yemen rank
20th
Average cost of multi drug-resistant tuberculosis treatment over time
- Cameroon
- Yemen
How they compare
Cameroon currently reports 2,825 constant 2022 US$ against 2,510 constant 2022 US$ in Yemen, a difference of 315 constant 2022 US$.
That makes Cameroon's figure about 1.1 times Yemen's.
The two have swapped places 1 time across 7 shared years of data; in 2017 it was Yemen ahead.
Cameroon ranks 17th and Yemen ranks 20th of 92 countries.
Yemen has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cameroon | Yemen | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 867.67 constant 2022 US$ | 2,720 constant 2022 US$ | 1,852 constant 2022 US$ | Yemen |
| 2020s | 978.75 constant 2022 US$ | 3,052 constant 2022 US$ | 2,074 constant 2022 US$ | Yemen |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Cameroon or Yemen?
- Cameroon, at 2,825 constant 2022 US$ against 2,510 constant 2022 US$ in Yemen as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Cameroon and Yemen?
- 315 constant 2022 US$, with Cameroon ahead.
- How many years of comparable data are there for Cameroon and Yemen?
- 7 years are reported by both, from 2017 to 2024.
- How do Cameroon and Yemen rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Cameroon ranks 17th and Yemen ranks 20th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.